For decades, medical textbooks have taught that obesity-linked Type 2 diabetes develops like a slow-burning fire, where chronic low-grade inflammation gradually damages insulin-producing cells in the pancreas over months and years. Now, a landmark study led by scientists at the Indian Institute of Technology (IIT) Kanpur has overturned that long-standing assumption. Researchers from the Department of Biological Sciences and Bioengineering at IIT Kanpur have discovered that immune cells stationed inside the pancreas can actively silence insulin secretion within just a few minutes—without triggering any classical inflammatory signals. Published in the prestigious Journal of Clinical Investigation, the findings reveal a previously unknown, high-speed biological circuit that could reshape how pharmaceutical researchers design next-generation treatments for obesity and Type 2 diabetes across India and the world.

How Pancreatic Immune Cells Block Insulin Within Minutes

Inside the human pancreas, insulin-producing beta cells sit right next to specialised tissue-resident immune cells called macrophages. Until now, scientists believed macrophages primarily harmed beta cells during obesity by releasing inflammatory proteins that slowly eroded cellular health over long periods. However, the IIT Kanpur research team—led by Dr. Sai Prasad Pydi alongside co-first authors Simran Singh and Ashish Kumar—demonstrated that macrophages engage in direct, instantaneous chemical crosstalk with neighbouring beta cells. As Dr. Pydi explained in the institute’s official release, immune cells located next to beta cells can switch off insulin release within minutes by sending a direct molecular instruction rather than causing slow structural damage.

The Molecular Mechanism: GPR18 Receptor and Sphingolipid Messengers

To understand how this rapid shutdown happens, the researchers traced the exact chain of command inside pancreatic islets. The process begins at a specific surface receptor on macrophages known as GPR18. When the signalling pathway linked to GPR18 is switched on inside macrophages, these immune cells rapidly manufacture and release a class of fat molecules called sphingolipids. Instead of lingering harmlessly, these sphingolipid messengers are quickly absorbed by neighbouring beta cells through a dedicated fatty-acid transporter on their outer membrane. Once inside the beta cells, the absorbed lipids directly disrupt the internal cellular machinery responsible for releasing insulin into the bloodstream, causing insulin secretion to drop sharply even when blood glucose levels demand it.

Confirmed in Human Pancreatic Tissue With US Collaborators

A critical question in biomedical research is whether mechanisms observed in laboratory mice hold true in the human body. Using precision genetic techniques in mouse models, the IIT Kanpur team first proved that turning the macrophage pathway on suppressed insulin release, whereas switching it off restored healthy insulin secretion. To validate these results in humans, the researchers collaborated with scientists at the Indiana Biosciences Research Institute in the United States to examine donated human pancreatic tissue. Their analysis confirmed that GPR18 receptors are heavily concentrated in the immune cells of human pancreatic islets, and artificially activating this same pathway in human tissue immediately blocked insulin secretion—proving that this biological circuit operates identically in people.

Why This Discovery Matters for Future Type 2 Diabetes Drugs

While the IIT Kanpur study is a foundational discovery rather than an immediate medicine on pharmacy shelves, it gives drug developers three distinct, actionable targets to protect natural insulin production. By designing targeted molecules that either block the GPR18 receptor on immune cells, interrupt sphingolipid production, or prevent the beta-cell transporter from absorbing those lipids, future therapies could stop immune cells from silencing beta cells in people living with obesity and early-stage Type 2 diabetes. For a country like India—often referred to as the diabetes capital of the world, with over 100 million adults living with diabetes—preserving the body’s own insulin-secreting capacity represents a major shift from merely managing blood sugar symptoms to protecting pancreatic function at its source.